, a bio/informatics shared resource is still "open for business" - Visit the CDS website


Carrie Jones
Last active: 3/18/2020

Profile

None provided

Publications

The following timeline graph is generated from all co-authored publications.

Featured publications are shown below:

  1. Selective allosteric modulation of muscarinic acetylcholine receptors for the treatment of schizophrenia and substance use disorders. Teal LB, Gould RW, Felts AS, Jones CK (2019) Adv Pharmacol : 153-196
    › Primary publication · 31378251 (PubMed)
  2. The Role of Estrogen in Brain and Cognitive Aging. Russell JK, Jones CK, Newhouse PA (2019) Neurotherapeutics 16(3): 649-665
    › Primary publication · 31364065 (PubMed) · PMC6694379 (PubMed Central)
  3. SAR inspired by aldehyde oxidase (AO) metabolism: Discovery of novel, CNS penetrant tricyclic M PAMs. Chopko TC, Han C, Gregro AR, Engers DW, Felts AS, Poslusney MS, Bollinger KA, Morrison RD, Bubser M, Lamsal A, Luscombe VB, Cho HP, Schnetz-Boutaud NC, Rodriguez AL, Chang S, Daniels JS, Stec DF, Niswender CM, Jones CK, Wood MR, Wood MW, Duggan ME, Brandon NJ, Conn PJ, Bridges TM, Lindsley CW, Melancon BJ (2019) Bioorg Med Chem Lett 29(16): 2224-2228
    › Primary publication · 31248774 (PubMed) · PMC6690795 (PubMed Central)
  4. VU6005806/AZN-00016130, an advanced M positive allosteric modulator (PAM) profiled as a potential preclinical development candidate. Engers DW, Melancon BJ, Gregro AR, Bertron JL, Bollinger SR, Felts AS, Konkol LC, Wood MR, Bollinger KA, Luscombe VB, Rodriguez AL, Jones CK, Bubser M, Yohn SE, Wood MW, Brandon NJ, Dugan ME, Niswender CM, Jeffrey Conn P, Bridges TM, Lindsley CW (2019) Bioorg Med Chem Lett 29(14): 1714-1718
    › Primary publication · 31113706 (PubMed)
  5. Discovery of VU2957 (Valiglurax): An mGlu Positive Allosteric Modulator Evaluated as a Preclinical Candidate for the Treatment of Parkinson's Disease. Panarese JD, Engers DW, Wu YJ, Bronson JJ, Macor JE, Chun A, Rodriguez AL, Felts AS, Engers JL, Loch MT, Emmitte KA, Castelhano AL, Kates MJ, Nader MA, Jones CK, Blobaum AL, Conn PJ, Niswender CM, Hopkins CR, Lindsley CW (2019) ACS Med Chem Lett 10(3): 255-260
    › Primary publication · 30891122 (PubMed) · PMC6421540 (PubMed Central)
  6. Disabling the Gβγ-SNARE interaction disrupts GPCR-mediated presynaptic inhibition, leading to physiological and behavioral phenotypes. Zurawski Z, Thompson Gray AD, Brady LJ, Page B, Church E, Harris NA, Dohn MR, Yim YY, Hyde K, Mortlock DP, Jones CK, Winder DG, Alford S, Hamm HE (2019) Sci Signal 12(569)
    › Primary publication · 30783011 (PubMed)
  7. The discovery of VU0652957 (VU2957, Valiglurax): SAR and DMPK challenges en route to an mGlu PAM development candidate. Panarese JD, Engers DW, Wu YJ, Guernon JM, Chun A, Gregro AR, Bender AM, Capstick RA, Wieting JM, Bronson JJ, Macor JE, Westphal R, Soars M, Engers JE, Felts AS, Rodriguez AL, Emmitte KA, Jones CK, Blobaum AL, Conn PJ, Niswender CM, Hopkins CR, Lindsley CW (2019) Bioorg Med Chem Lett 29(2): 342-346
    › Primary publication · 30503632 (PubMed)
  8. Analgesic Effects of the GIRK Activator, VU0466551, Alone and in Combination with Morphine in Acute and Persistent Pain Models. Abney KK, Bubser M, Du Y, Kozek KA, Bridges TM, Linsdley CW, Daniels JS, Morrison RD, Wickman K, Hopkins CR, Jones CK, Weaver CD (2019) ACS Chem Neurosci 10(3): 1294-1299
    › Primary publication · 30474955 (PubMed) · PMC6765219 (PubMed Central)
  9. Discovery of 4-alkoxy-6-methylpicolinamide negative allosteric modulators of metabotropic glutamate receptor subtype 5. Felts AS, Bollinger KA, Brassard CJ, Rodriguez AL, Morrison RD, Scott Daniels J, Blobaum AL, Niswender CM, Jones CK, Conn PJ, Emmitte KA, Lindsley CW (2019) Bioorg Med Chem Lett 29(1): 47-50
    › Primary publication · 30446311 (PubMed) · PMC6295259 (PubMed Central)
  10. Discovery, Structure-Activity Relationship, and Biological Characterization of a Novel Series of 6-((1 H-Pyrazolo[4,3- b]pyridin-3-yl)amino)-benzo[ d]isothiazole-3-carboxamides as Positive Allosteric Modulators of the Metabotropic Glutamate Receptor 4 (mGlu). Bollinger SR, Engers DW, Panarese JD, West M, Engers JL, Loch MT, Rodriguez AL, Blobaum AL, Jones CK, Thompson Gray A, Conn PJ, Lindsley CW, Niswender CM, Hopkins CR (2019) J Med Chem 62(1): 342-358
    › Primary publication · 30247901 (PubMed)
  11. Activation of the mGlu metabotropic glutamate receptor has antipsychotic-like effects and is required for efficacy of M muscarinic receptor allosteric modulators. Yohn SE, Foster DJ, Covey DP, Moehle MS, Galbraith J, Garcia-Barrantes PM, Cho HP, Bubser M, Blobaum AL, Joffe ME, Cheer JF, Jones CK, Lindsley CW, Conn PJ (2018) Mol Psychiatry
    › Primary publication · 30116027 (PubMed) · PMC6588501 (PubMed Central)
  12. Corrigendum to "Challenges in the development of an M PAM preclinical candidate: The discovery, SAR, and biological characterization of a series of azetidine-derived tertiary amides" [Bioorg. Med. Chem. Lett. 27(23) (2017) 5179-5184]. Tarr JC, Wood MR, Noetzel MJ, Melancon BJ, Lamsal A, Luscombe VB, Rodriguez AL, Byers FW, Chang S, Cho HP, Engers DW, Jones CK, Niswender CM, Wood MW, Brandon NJ, Duggan ME, Conn PJ, Bridges TM, Lindsley CW (2018) Bioorg Med Chem Lett 28(17): 3014
    › Primary publication · 30076050 (PubMed) · PMC6690053 (PubMed Central)
  13. Total RNA Sequencing of Rett Syndrome Autopsy Samples Identifies the M Muscarinic Receptor as a Novel Therapeutic Target. Gogliotti RG, Fisher NM, Stansley BJ, Jones CK, Lindsley CW, Conn PJ, Niswender CM (2018) J Pharmacol Exp Ther 365(2): 291-300
    › Primary publication · 29523700 (PubMed) · PMC5878667 (PubMed Central)
  14. Muscarinic M receptors modulate ethanol seeking in rats. Berizzi AE, Perry CJ, Shackleford DM, Lindsley CW, Jones CK, Chen NA, Sexton PM, Christopoulos A, Langmead CJ, Lawrence AJ (2018) Neuropsychopharmacology 43(7): 1510-1517
    › Primary publication · 29483658 (PubMed) · PMC5983544 (PubMed Central)
  15. Cholinergic Projections to the Substantia Nigra Pars Reticulata Inhibit Dopamine Modulation of Basal Ganglia through the M Muscarinic Receptor. Moehle MS, Pancani T, Byun N, Yohn SE, Wilson GH, Dickerson JW, Remke DH, Xiang Z, Niswender CM, Wess J, Jones CK, Lindsley CW, Rook JM, Conn PJ (2017) Neuron 96(6): 1358-1372.e4
    › Primary publication · 29268098 (PubMed) · PMC5753765 (PubMed Central)
  16. Challenges in the development of an M PAM preclinical candidate: The discovery, SAR, and biological characterization of a series of azetidine-derived tertiary amides. Tarr JC, Wood MR, Noetzel MJ, Melancon BJ, Lamsal A, Luscombe VB, Rodriguez AL, Byers FW, Chang S, Cho HP, Engers DW, Jones CK, Niswender CM, Wood MW, Brandon NJ, Duggan ME, Conn PJ, Bridges TM, Lindsley CW (2017) Bioorg Med Chem Lett 27(23): 5179-5184
    › Primary publication · 29089231 (PubMed) · PMC6542369 (PubMed Central)
  17. Discovery of VU6005649, a CNS Penetrant mGlu Receptor PAM Derived from a Series of Pyrazolo[1,5-]pyrimidines. Abe M, Seto M, Gogliotti RG, Loch MT, Bollinger KA, Chang S, Engelberg EM, Luscombe VB, Harp JM, Bubser M, Engers DW, Jones CK, Rodriguez AL, Blobaum AL, Conn PJ, Niswender CM, Lindsley CW (2017) ACS Med Chem Lett 8(10): 1110-1115
    › Primary publication · 29057060 (PubMed) · PMC5641958 (PubMed Central)
  18. Selective inhibition of M muscarinic acetylcholine receptors attenuates cocaine self-administration in rats. Gunter BW, Gould RW, Bubser M, McGowan KM, Lindsley CW, Jones CK (2018) Addict Biol 23(5): 1106-1116
    › Primary publication · 29044937 (PubMed) · PMC5906200 (PubMed Central)
  19. Discovery of imidazo[1,2-a]-, [1,2,4]triazolo[4,3-a]-, and [1,2,4]triazolo[1,5-a]pyridine-8-carboxamide negative allosteric modulators of metabotropic glutamate receptor subtype 5. Felts AS, Rodriguez AL, Morrison RD, Bollinger KA, Venable DF, Blobaum AL, Byers FW, Thompson Gray A, Daniels JS, Niswender CM, Jones CK, Conn PJ, Lindsley CW, Emmitte KA (2017) Bioorg Med Chem Lett 27(21): 4858-4866
    › Primary publication · 28958625 (PubMed) · PMC5716465 (PubMed Central)
  20. Design and Synthesis of -Aryl Phenoxyethoxy Pyridinones as Highly Selective and CNS Penetrant mGlu NAMs. Engers JL, Bollinger KA, Weiner RL, Rodriguez AL, Long MF, Breiner MM, Chang S, Bollinger SR, Bubser M, Jones CK, Morrison RD, Bridges TM, Blobaum AL, Niswender CM, Conn PJ, Emmitte KA, Lindsley CW (2017) ACS Med Chem Lett 8(9): 925-930
    › Primary publication · 28947938 (PubMed) · PMC5601378 (PubMed Central)
  21. Design and Synthesis of mGlu NAMs with Improved Potency and CNS Penetration Based on a Truncated Picolinamide Core. Bollinger KA, Felts AS, Brassard CJ, Engers JL, Rodriguez AL, Weiner RL, Cho HP, Chang S, Bubser M, Jones CK, Blobaum AL, Niswender CM, Conn PJ, Emmitte KA, Lindsley CW (2017) ACS Med Chem Lett 8(9): 919-924
    › Primary publication · 28947937 (PubMed) · PMC5601377 (PubMed Central)
  22. mGlu potentiation rescues cognitive, social, and respiratory phenotypes in a mouse model of Rett syndrome. Gogliotti RG, Senter RK, Fisher NM, Adams J, Zamorano R, Walker AG, Blobaum AL, Engers DW, Hopkins CR, Daniels JS, Jones CK, Lindsley CW, Xiang Z, Conn PJ, Niswender CM (2017) Sci Transl Med 9(403)
    › Primary publication · 28814546 (PubMed) · PMC5654528 (PubMed Central)
  23. Cognitive enhancement and antipsychotic-like activity following repeated dosing with the selective M PAM VU0467154. Gould RW, Grannan MD, Gunter BW, Ball J, Bubser M, Bridges TM, Wess J, Wood MW, Brandon NJ, Duggan ME, Niswender CM, Lindsley CW, Conn PJ, Jones CK (2018) Neuropharmacology : 492-502
    › Primary publication · 28729220 (PubMed) · PMC6756753 (PubMed Central)
  24. Discovery of N-(5-Fluoropyridin-2-yl)-6-methyl-4-(pyrimidin-5-yloxy)picolinamide (VU0424238): A Novel Negative Allosteric Modulator of Metabotropic Glutamate Receptor Subtype 5 Selected for Clinical Evaluation. Felts AS, Rodriguez AL, Blobaum AL, Morrison RD, Bates BS, Thompson Gray A, Rook JM, Tantawy MN, Byers FW, Chang S, Venable DF, Luscombe VB, Tamagnan GD, Niswender CM, Daniels JS, Jones CK, Conn PJ, Lindsley CW, Emmitte KA (2017) J Med Chem 60(12): 5072-5085
    › Primary publication · 28530802 (PubMed) · PMC5484149 (PubMed Central)
  25. Challenges in the development of an M PAM preclinical candidate: The discovery, SAR, and in vivo characterization of a series of 3-aminoazetidine-derived amides. Tarr JC, Wood MR, Noetzel MJ, Bertron JL, Weiner RL, Rodriguez AL, Lamsal A, Byers FW, Chang S, Cho HP, Jones CK, Niswender CM, Wood MW, Brandon NJ, Duggan ME, Conn PJ, Bridges TM, Lindsley CW (2017) Bioorg Med Chem Lett 27(13): 2990-2995
    › Primary publication · 28522253 (PubMed) · PMC5518475 (PubMed Central)
  26. OCD candidate gene /EAAT3 impacts basal ganglia-mediated activity and stereotypic behavior. Zike ID, Chohan MO, Kopelman JM, Krasnow EN, Flicker D, Nautiyal KM, Bubser M, Kellendonk C, Jones CK, Stanwood G, Tanaka KF, Moore H, Ahmari SE, Veenstra-VanderWeele J (2017) Proc Natl Acad Sci U S A 114(22): 5719-5724
    › Primary publication · 28507136 (PubMed) · PMC5465902 (PubMed Central)
  27. Optimization of M positive allosteric modulators (PAMs): The discovery of VU0476406, a non-human primate in vivo tool compound for translational pharmacology. Melancon BJ, Wood MR, Noetzel MJ, Nance KD, Engelberg EM, Han C, Lamsal A, Chang S, Cho HP, Byers FW, Bubser M, Jones CK, Niswender CM, Wood MW, Engers DW, Wu D, Brandon NJ, Duggan ME, Conn PJ, Bridges TM, Lindsley CW (2017) Bioorg Med Chem Lett 27(11): 2296-2301
    › Primary publication · 28442253 (PubMed) · PMC5508548 (PubMed Central)
  28. Corrigendum to "Novel GlyT1 inhibitor chemotypes by scaffold hopping. Part 2: Development of a [3.3.0]-based series and other piperidine bioisosteres" [Bioorg. Med. Chem. Lett. 24 (2014) 1062-1066]. Sheffler DJ, Nedelcovych MT, Williams R, Turner SC, Duerk BB, Robbins MR, Jadhav SB, Niswender CM, Jones CK, Conn PJ, Nathan Daniels R, Lindsley CW (2017) Bioorg Med Chem Lett 27(9): 2079
    › Primary publication · 28347668 (PubMed)
  29. Classics in Chemical Neuroscience: Xanomeline. Bender AM, Jones CK, Lindsley CW (2017) ACS Chem Neurosci 8(3): 435-443
    › Primary publication · 28141924 (PubMed)
  30. Diverse Effects on M Signaling and Adverse Effect Liability within a Series of M Ago-PAMs. Rook JM, Abe M, Cho HP, Nance KD, Luscombe VB, Adams JJ, Dickerson JW, Remke DH, Garcia-Barrantes PM, Engers DW, Engers JL, Chang S, Foster JJ, Blobaum AL, Niswender CM, Jones CK, Conn PJ, Lindsley CW (2017) ACS Chem Neurosci 8(4): 866-883
    › Primary publication · 28001356 (PubMed) · PMC5460155 (PubMed Central)
  31. Challenges in the development of an M PAM in vivo tool compound: The discovery of VU0467154 and unexpected DMPK profiles of close analogs. Wood MR, Noetzel MJ, Poslusney MS, Melancon BJ, Tarr JC, Lamsal A, Chang S, Luscombe VB, Weiner RL, Cho HP, Bubser M, Jones CK, Niswender CM, Wood MW, Engers DW, Brandon NJ, Duggan ME, Conn PJ, Bridges TM, Lindsley CW (2017) Bioorg Med Chem Lett 27(2): 171-175
    › Primary publication · 27939174 (PubMed) · PMC5340297 (PubMed Central)
  32. Antipsychotic-like Effects of M4 Positive Allosteric Modulators Are Mediated by CB2 Receptor-Dependent Inhibition of Dopamine Release. Foster DJ, Wilson JM, Remke DH, Mahmood MS, Uddin MJ, Wess J, Patel S, Marnett LJ, Niswender CM, Jones CK, Xiang Z, Lindsley CW, Rook JM, Conn PJ (2016) Neuron 91(6): 1244-1252
    › Primary publication · 27618677 (PubMed) · PMC5033724 (PubMed Central)
  33. Prefrontal Cortex-Mediated Impairments in a Genetic Model of NMDA Receptor Hypofunction Are Reversed by the Novel M PAM VU6004256. Grannan MD, Mielnik CA, Moran SP, Gould RW, Ball J, Lu Z, Bubser M, Ramsey AJ, Abe M, Cho HP, Nance KD, Blobaum AL, Niswender CM, Conn PJ, Lindsley CW, Jones CK (2016) ACS Chem Neurosci 7(12): 1706-1716
    › Primary publication · 27617634 (PubMed) · PMC5231396 (PubMed Central)
  34. Ligand-based virtual screen for the discovery of novel M5 inhibitor chemotypes. Geanes AR, Cho HP, Nance KD, McGowan KM, Conn PJ, Jones CK, Meiler J, Lindsley CW (2016) Bioorg Med Chem Lett 26(18): 4487-4491
    › Primary publication · 27503678 (PubMed) · PMC4996684 (PubMed Central)
  35. Discovery and optimization of a novel series of highly CNS penetrant M4 PAMs based on a 5,6-dimethyl-4-(piperidin-1-yl)thieno[2,3-d]pyrimidine core. Wood MR, Noetzel MJ, Engers JL, Bollinger KA, Melancon BJ, Tarr JC, Han C, West M, Gregro AR, Lamsal A, Chang S, Ajmera S, Smith E, Chase P, Hodder PS, Bubser M, Jones CK, Hopkins CR, Emmitte KA, Niswender CM, Wood MW, Duggan ME, Conn PJ, Bridges TM, Lindsley CW (2016) Bioorg Med Chem Lett 26(13): 3029-3033
    › Primary publication · 27185330 (PubMed) · PMC4955361 (PubMed Central)
  36. Discovery of 3-aminopicolinamides as metabotropic glutamate receptor subtype 4 (mGlu4) positive allosteric modulator warheads engendering CNS exposure and in vivo efficacy. Gogliotti RD, Engers DW, Garcia-Barrantes PM, Panarese JD, Gentry PR, Blobaum AL, Morrison RD, Daniels JS, Thompson AD, Jones CK, Conn PJ, Niswender CM, Lindsley CW, Hopkins CR (2016) Bioorg Med Chem Lett 26(12): 2915-2919
    › Primary publication · 27131990 (PubMed) · PMC4899947 (PubMed Central)
  37. N-Alkylpyrido[1',2':1,5]pyrazolo-[4,3-d]pyrimidin-4-amines: A new series of negative allosteric modulators of mGlu1/5 with CNS exposure in rodents. Felts AS, Rodriguez AL, Morrison RD, Venable DF, Blobaum AL, Byers FW, Daniels JS, Niswender CM, Jones CK, Conn PJ, Lindsley CW, Emmitte KA (2016) Bioorg Med Chem Lett 26(8): 1894-900
    › Primary publication · 26988308 (PubMed) · PMC4824313 (PubMed Central)
  38. mGlu5 positive allosteric modulation normalizes synaptic plasticity defects and motor phenotypes in a mouse model of Rett syndrome. Gogliotti RG, Senter RK, Rook JM, Ghoshal A, Zamorano R, Malosh C, Stauffer SR, Bridges TM, Bartolome JM, Daniels JS, Jones CK, Lindsley CW, Conn PJ, Niswender CM (2016) Hum Mol Genet 25(10): 1990-2004
    › Primary publication · 26936821 (PubMed) · PMC5062588 (PubMed Central)
  39. An mGlu5-Positive Allosteric Modulator Rescues the Neuroplasticity Deficits in a Genetic Model of NMDA Receptor Hypofunction in Schizophrenia. Balu DT, Li Y, Takagi S, Presti KT, Ramikie TS, Rook JM, Jones CK, Lindsley CW, Conn PJ, Bolshakov VY, Coyle JT (2016) Neuropsychopharmacology 41(8): 2052-61
    › Primary publication · 26741285 (PubMed) · PMC4908650 (PubMed Central)
  40. Preliminary investigation of 6,7-dihydropyrazolo[1,5-a]pyrazin-4-one derivatives as a novel series of mGlu5 receptor positive allosteric modulators with efficacy in preclinical models of schizophrenia. Conde-Ceide S, Alcázar J, Alonso de Diego SA, López S, Martín-Martín ML, Martínez-Viturro CM, Pena MA, Tong HM, Lavreysen H, Mackie C, Bridges TM, Daniels JS, Niswender CM, Jones CK, Macdonald GJ, Steckler T, Conn PJ, Stauffer SR, Lindsley CW, Bartolomé-Nebreda JM (2016) Bioorg Med Chem Lett 26(2): 429-434
    › Primary publication · 26684851 (PubMed) · PMC4835042 (PubMed Central)
  41. State-dependent alterations in sleep/wake architecture elicited by the M4 PAM VU0467154 - Relation to antipsychotic-like drug effects. Gould RW, Nedelcovych MT, Gong X, Tsai E, Bubser M, Bridges TM, Wood MR, Duggan ME, Brandon NJ, Dunlop J, Wood MW, Ivarsson M, Noetzel MJ, Daniels JS, Niswender CM, Lindsley CW, Conn PJ, Jones CK (2016) Neuropharmacology : 244-53
    › Primary publication · 26617071 (PubMed) · PMC4809053 (PubMed Central)
  42. Allosteric activation of M4 muscarinic receptors improve behavioral and physiological alterations in early symptomatic YAC128 mice. Pancani T, Foster DJ, Moehle MS, Bichell TJ, Bradley E, Bridges TM, Klar R, Poslusney M, Rook JM, Daniels JS, Niswender CM, Jones CK, Wood MR, Bowman AB, Lindsley CW, Xiang Z, Conn PJ (2015) Proc Natl Acad Sci U S A 112(45): 14078-83
    › Primary publication · 26508634 (PubMed) · PMC4653197 (PubMed Central)
  43. VU0477573: Partial Negative Allosteric Modulator of the Subtype 5 Metabotropic Glutamate Receptor with In Vivo Efficacy. Nickols HH, Yuh JP, Gregory KJ, Morrison RD, Bates BS, Stauffer SR, Emmitte KA, Bubser M, Peng W, Nedelcovych MT, Thompson A, Lv X, Xiang Z, Daniels JS, Niswender CM, Lindsley CW, Jones CK, Conn PJ (2016) J Pharmacol Exp Ther 356(1): 123-36
    › Primary publication · 26503377 (PubMed) · PMC4702078 (PubMed Central)
  44. Acyl dihydropyrazolo[1,5-a]pyrimidinones as metabotropic glutamate receptor 5 positive allosteric modulators. Malosh C, Turlington M, Bridges TM, Rook JM, Noetzel MJ, Vinson PN, Steckler T, Lavreysen H, Mackie C, Bartolomé-Nebreda JM, Conde-Ceide S, Martínez-Viturro CM, Piedrafita M, Sánchez-Casado MR, Macdonald GJ, Daniels JS, Jones CK, Niswender CM, Conn PJ, Lindsley CW, Stauffer SR (2015) Bioorg Med Chem Lett 25(22): 5115-20
    › Primary publication · 26475522 (PubMed) · PMC4634704 (PubMed Central)
  45. Discovery of a Selective and CNS Penetrant Negative Allosteric Modulator of Metabotropic Glutamate Receptor Subtype 3 with Antidepressant and Anxiolytic Activity in Rodents. Engers JL, Rodriguez AL, Konkol LC, Morrison RD, Thompson AD, Byers FW, Blobaum AL, Chang S, Venable DF, Loch MT, Niswender CM, Daniels JS, Jones CK, Conn PJ, Lindsley CW, Emmitte KA (2015) J Med Chem 58(18): 7485-500
    › Primary publication · 26335039 (PubMed) · PMC4809247 (PubMed Central)
  46. Partial mGlu₅ Negative Allosteric Modulators Attenuate Cocaine-Mediated Behaviors and Lack Psychotomimetic-Like Effects. Gould RW, Amato RJ, Bubser M, Joffe ME, Nedelcovych MT, Thompson AD, Nickols HH, Yuh JP, Zhan X, Felts AS, Rodriguez AL, Morrison RD, Byers FW, Rook JM, Daniels JS, Niswender CM, Conn PJ, Emmitte KA, Lindsley CW, Jones CK (2016) Neuropsychopharmacology 41(4): 1166-78
    › Primary publication · 26315507 (PubMed) · PMC4748441 (PubMed Central)
  47. Further optimization of the mGlu5 PAM clinical candidate VU0409551/JNJ-46778212: Progress and challenges towards a back-up compound. Zhou Y, Malosh C, Conde-Ceide S, Martínez-Viturro CM, Alcázar J, Lavreysen H, Mackie C, Bridges TM, Daniels JS, Niswender CM, Jones CK, Macdonald GJ, Steckler T, Conn PJ, Stauffer SR, Bartolomé-Nebreda JM, Lindsley CW (2015) Bioorg Med Chem Lett 25(17): 3515-9
    › Primary publication · 26183084 (PubMed) · PMC4535329 (PubMed Central)
  48. Discovery of VU0409551/JNJ-46778212: An mGlu5 Positive Allosteric Modulator Clinical Candidate Targeting Schizophrenia. Conde-Ceide S, Martínez-Viturro CM, Alcázar J, Garcia-Barrantes PM, Lavreysen H, Mackie C, Vinson PN, Rook JM, Bridges TM, Daniels JS, Megens A, Langlois X, Drinkenburg WH, Ahnaou A, Niswender CM, Jones CK, Macdonald GJ, Steckler T, Conn PJ, Stauffer SR, Bartolomé-Nebreda JM, Lindsley CW (2015) ACS Med Chem Lett 6(6): 716-20
    › Primary publication · 26157544 (PubMed) · PMC4492464 (PubMed Central)
  49. Potentiation of M1 Muscarinic Receptor Reverses Plasticity Deficits and Negative and Cognitive Symptoms in a Schizophrenia Mouse Model. Ghoshal A, Rook JM, Dickerson JW, Roop GN, Morrison RD, Jalan-Sakrikar N, Lamsal A, Noetzel MJ, Poslusney MS, Wood MR, Melancon BJ, Stauffer SR, Xiang Z, Daniels JS, Niswender CM, Jones CK, Lindsley CW, Conn PJ (2016) Neuropsychopharmacology 41(2): 598-610
    › Primary publication · 26108886 (PubMed) · PMC5130135 (PubMed Central)
  50. Biased mGlu5-Positive Allosteric Modulators Provide In Vivo Efficacy without Potentiating mGlu5 Modulation of NMDAR Currents. Rook JM, Xiang Z, Lv X, Ghoshal A, Dickerson JW, Bridges TM, Johnson KA, Foster DJ, Gregory KJ, Vinson PN, Thompson AD, Byun N, Collier RL, Bubser M, Nedelcovych MT, Gould RW, Stauffer SR, Daniels JS, Niswender CM, Lavreysen H, Mackie C, Conde-Ceide S, Alcazar J, Bartolomé-Nebreda JM, Macdonald GJ, Talpos JC, Steckler T, Jones CK, Lindsley CW, Conn PJ (2015) Neuron 86(4): 1029-1040
    › Primary publication · 25937172 (PubMed) · PMC4443790 (PubMed Central)
  51. Pharmacological stimulation of metabotropic glutamate receptor type 4 in a rat model of Parkinson's disease and L-DOPA-induced dyskinesia: Comparison between a positive allosteric modulator and an orthosteric agonist. Iderberg H, Maslava N, Thompson AD, Bubser M, Niswender CM, Hopkins CR, Lindsley CW, Conn PJ, Jones CK, Cenci MA (2015) Neuropharmacology : 121-9
    › Primary publication · 25749357 (PubMed) · PMC4466038 (PubMed Central)
  52. Discovery and SAR of novel series of imidazopyrimidinones and dihydroimidazopyrimidinones as positive allosteric modulators of the metabotropic glutamate receptor 5 (mGlu5). Martín-Martín ML, Bartolomé-Nebreda JM, Conde-Ceide S, Alonso de Diego SA, López S, Martínez-Viturro CM, Tong HM, Lavreysen H, Macdonald GJ, Steckler T, Mackie C, Bridges TM, Daniels JS, Niswender CM, Noetzel MJ, Jones CK, Conn PJ, Lindsley CW, Stauffer SR (2015) Bioorg Med Chem Lett 25(6): 1310-7
    › Primary publication · 25683622 (PubMed) · PMC4399811 (PubMed Central)
  53. A rodent model of traumatic stress induces lasting sleep and quantitative electroencephalographic disturbances. Nedelcovych MT, Gould RW, Zhan X, Bubser M, Gong X, Grannan M, Thompson AT, Ivarsson M, Lindsley CW, Conn PJ, Jones CK (2015) ACS Chem Neurosci 6(3): 485-93
    › Primary publication · 25581551 (PubMed) · PMC4403733 (PubMed Central)
  54. Discovery of (S)-2-cyclopentyl-N-((1-isopropylpyrrolidin2-yl)-9-methyl-1-oxo-2,9-dihydro-1H-pyrrido[3,4-b]indole-4-carboxamide (VU0453379): a novel, CNS penetrant glucagon-like peptide 1 receptor (GLP-1R) positive allosteric modulator (PAM). Morris LC, Nance KD, Gentry PR, Days EL, Weaver CD, Niswender CM, Thompson AD, Jones CK, Locuson CW, Morrison RD, Daniels JS, Niswender KD, Lindsley CW (2014) J Med Chem 57(23): 10192-7
    › Primary publication · 25423411 (PubMed) · PMC4266362 (PubMed Central)
  55. Relationship between in vivo receptor occupancy and efficacy of metabotropic glutamate receptor subtype 5 allosteric modulators with different in vitro binding profiles. Rook JM, Tantawy MN, Ansari MS, Felts AS, Stauffer SR, Emmitte KA, Kessler RM, Niswender CM, Daniels JS, Jones CK, Lindsley CW, Conn PJ (2015) Neuropsychopharmacology 40(3): 755-65
    › Primary publication · 25241804 (PubMed) · PMC4289965 (PubMed Central)
  56. Discovery and Characterization of ML398, a Potent and Selective Antagonist of the D4 Receptor with in Vivo Activity. Berry CB, Bubser M, Jones CK, Hayes JP, Wepy JA, Locuson CW, Daniels JS, Lindsley CW, Hopkins CR (2014) ACS Med Chem Lett 5(9): 1060-4
    › Primary publication · 25221667 (PubMed) · PMC4160761 (PubMed Central)
  57. Selective activation of M4 muscarinic acetylcholine receptors reverses MK-801-induced behavioral impairments and enhances associative learning in rodents. Bubser M, Bridges TM, Dencker D, Gould RW, Grannan M, Noetzel MJ, Lamsal A, Niswender CM, Daniels JS, Poslusney MS, Melancon BJ, Tarr JC, Byers FW, Wess J, Duggan ME, Dunlop J, Wood MW, Brandon NJ, Wood MR, Lindsley CW, Conn PJ, Jones CK (2014) ACS Chem Neurosci 5(10): 920-42
    › Primary publication · 25137629 (PubMed) · PMC4324418 (PubMed Central)
  58. Chemical modulation of mutant mGlu1 receptors derived from deleterious GRM1 mutations found in schizophrenics. Cho HP, Garcia-Barrantes PM, Brogan JT, Hopkins CR, Niswender CM, Rodriguez AL, Venable DF, Morrison RD, Bubser M, Daniels JS, Jones CK, Conn PJ, Lindsley CW (2014) ACS Chem Biol 9(10): 2334-46
    › Primary publication · 25137254 (PubMed) · PMC4201332 (PubMed Central)
  59. Phospholipase D facilitates efficient entry of influenza virus, allowing escape from innate immune inhibition. Oguin TH, Sharma S, Stuart AD, Duan S, Scott SA, Jones CK, Daniels JS, Lindsley CW, Thomas PG, Brown HA (2014) J Biol Chem 289(37): 25405-17
    › Primary publication · 25065577 (PubMed) · PMC4162146 (PubMed Central)
  60. Discovery of VU0431316: a negative allosteric modulator of mGlu5 with activity in a mouse model of anxiety. Bates BS, Rodriguez AL, Felts AS, Morrison RD, Venable DF, Blobaum AL, Byers FW, Lawson KP, Daniels JS, Niswender CM, Jones CK, Conn PJ, Lindsley CW, Emmitte KA (2014) Bioorg Med Chem Lett 24(15): 3307-14
    › Primary publication · 24969015 (PubMed) · PMC4090943 (PubMed Central)
  61. Discovery and SAR of a novel series of metabotropic glutamate receptor 5 positive allosteric modulators with high ligand efficiency. Turlington M, Noetzel MJ, Bridges TM, Vinson PN, Steckler T, Lavreysen H, Mackie C, Bartolomé-Nebreda JM, Conde-Ceide S, Tong HM, Macdonald GJ, Daniels JS, Jones CK, Niswender CM, Conn PJ, Lindsley CW, Stauffer SR (2014) Bioorg Med Chem Lett 24(15): 3641-6
    › Primary publication · 24961642 (PubMed) · PMC4234308 (PubMed Central)
  62. Tetrahydronaphthyridine and dihydronaphthyridinone ethers as positive allosteric modulators of the metabotropic glutamate receptor 5 (mGlu₅). Turlington M, Malosh C, Jacobs J, Manka JT, Noetzel MJ, Vinson PN, Jadhav S, Herman EJ, Lavreysen H, Mackie C, Bartolomé-Nebreda JM, Conde-Ceide S, Martín-Martín ML, Tong HM, López S, MacDonald GJ, Steckler T, Daniels JS, Weaver CD, Niswender CM, Jones CK, Conn PJ, Lindsley CW, Stauffer SR (2014) J Med Chem 57(13): 5620-37
    › Primary publication · 24914612 (PubMed) · PMC4096224 (PubMed Central)
  63. Novel GlyT1 inhibitor chemotypes by scaffold hopping. Part 2: development of a [3.3.0]-based series and other piperidine bioisosteres. Sheffler DJ, Nedelcovych MT, Williams R, Turner SC, Duerk BB, Robbins MR, Jadhav SB, Niswender CM, Jones CK, Conn PJ, Daniels RN, Lindsley CW (2014) Bioorg Med Chem Lett 24(4): 1062-6
    › Primary publication · 24462664 (PubMed) · PMC3951244 (PubMed Central)
  64. Novel GlyT1 inhibitor chemotypes by scaffold hopping. Part 1: development of a potent and CNS penetrant [3.1.0]-based lead. Jones CK, Sheffler DJ, Williams R, Jadhav SB, Felts AS, Morrison RD, Niswender CM, Daniels JS, Conn PJ, Lindsley CW (2014) Bioorg Med Chem Lett 24(4): 1067-70
    › Primary publication · 24461352 (PubMed) · PMC3951249 (PubMed Central)
  65. Antipsychotic drug-like effects of the selective M4 muscarinic acetylcholine receptor positive allosteric modulator VU0152100. Byun NE, Grannan M, Bubser M, Barry RL, Thompson A, Rosanelli J, Gowrishankar R, Kelm ND, Damon S, Bridges TM, Melancon BJ, Tarr JC, Brogan JT, Avison MJ, Deutch AY, Wess J, Wood MR, Lindsley CW, Gore JC, Conn PJ, Jones CK (2014) Neuropsychopharmacology 39(7): 1578-93
    › Primary publication · 24442096 (PubMed) · PMC4023154 (PubMed Central)
  66. Discovery of VU0409106: A negative allosteric modulator of mGlu5 with activity in a mouse model of anxiety. Felts AS, Rodriguez AL, Morrison RD, Venable DF, Manka JT, Bates BS, Blobaum AL, Byers FW, Daniels JS, Niswender CM, Jones CK, Conn PJ, Lindsley CW, Emmitte KA (2013) Bioorg Med Chem Lett 23(21): 5779-85
    › Primary publication · 24074843 (PubMed) · PMC3846293 (PubMed Central)
  67. Heterotropic activation of the midazolam hydroxylase activity of CYP3A by a positive allosteric modulator of mGlu5: in vitro to in vivo translation and potential impact on clinically relevant drug-drug interactions. Blobaum AL, Bridges TM, Byers FW, Turlington ML, Mattmann ME, Morrison RD, Mackie C, Lavreysen H, Bartolomé JM, Macdonald GJ, Steckler T, Jones CK, Niswender CM, Conn PJ, Lindsley CW, Stauffer SR, Daniels JS (2013) Drug Metab Dispos 41(12): 2066-75
    › Primary publication · 24003250 (PubMed) · PMC3834130 (PubMed Central)
  68. N-aryl piperazine metabotropic glutamate receptor 5 positive allosteric modulators possess efficacy in preclinical models of NMDA hypofunction and cognitive enhancement. Gregory KJ, Herman EJ, Ramsey AJ, Hammond AS, Byun NE, Stauffer SR, Manka JT, Jadhav S, Bridges TM, Weaver CD, Niswender CM, Steckler T, Drinkenburg WH, Ahnaou A, Lavreysen H, Macdonald GJ, Bartolomé JM, Mackie C, Hrupka BJ, Caron MG, Daigle TL, Lindsley CW, Conn PJ, Jones CK (2013) J Pharmacol Exp Ther 347(2): 438-57
    › Primary publication · 23965381 (PubMed) · PMC3807069 (PubMed Central)
  69. Biotransformation of a novel positive allosteric modulator of metabotropic glutamate receptor subtype 5 contributes to seizure-like adverse events in rats involving a receptor agonism-dependent mechanism. Bridges TM, Rook JM, Noetzel MJ, Morrison RD, Zhou Y, Gogliotti RD, Vinson PN, Xiang Z, Jones CK, Niswender CM, Lindsley CW, Stauffer SR, Conn PJ, Daniels JS (2013) Drug Metab Dispos 41(9): 1703-14
    › Primary publication · 23821185 (PubMed) · PMC3876804 (PubMed Central)
  70. Substituted 1-Phenyl-3-(pyridin-2-yl)urea negative allosteric modulators of mGlu5: discovery of a new tool compound VU0463841 with activity in rat models of cocaine addiction. Amato RJ, Felts AS, Rodriguez AL, Venable DF, Morrison RD, Byers FW, Daniels JS, Niswender CM, Conn PJ, Lindsley CW, Jones CK, Emmitte KA (2013) ACS Chem Neurosci 4(8): 1217-28
    › Primary publication · 23682684 (PubMed) · PMC3750677 (PubMed Central)
  71. Discovery of N-Aryl Piperazines as Selective mGlu(5) Potentiators with Efficacy in a Rodent Model Predictive of Anti-Psychotic Activity. Zhou Y, Manka JT, Rodriguez AL, Weaver CD, Days EL, Vinson PN, Jadhav S, Hermann EJ, Jones CK, Conn PJ, Lindsley CW, Stauffer SR (2010) ACS Med Chem Lett 1(8): 433-438
    › Primary publication · 23308336 (PubMed) · PMC3539763 (PubMed Central)
  72. Emerging approaches for treatment of schizophrenia: modulation of cholinergic signaling. Foster DJ, Jones CK, Conn PJ (2012) Discov Med 14(79): 413-20
    › Primary publication · 23272693 (PubMed) · PMC3726271 (PubMed Central)
  73. Emerging approaches for treatment of schizophrenia: modulation of glutamatergic signaling. Noetzel MJ, Jones CK, Conn PJ (2012) Discov Med 14(78): 335-43
    › Primary publication · 23200065 (PubMed) · PMC3787874 (PubMed Central)
  74. Discovery of a selective M₄ positive allosteric modulator based on the 3-amino-thieno[2,3-b]pyridine-2-carboxamide scaffold: development of ML253, a potent and brain penetrant compound that is active in a preclinical model of schizophrenia. Le U, Melancon BJ, Bridges TM, Vinson PN, Utley TJ, Lamsal A, Rodriguez AL, Venable D, Sheffler DJ, Jones CK, Blobaum AL, Wood MR, Daniels JS, Conn PJ, Niswender CM, Lindsley CW, Hopkins CR (2013) Bioorg Med Chem Lett 23(1): 346-50
    › Primary publication · 23177787 (PubMed) · PMC3535830 (PubMed Central)
  75. Discovery and SAR of a novel series of non-MPEP site mGlu₅ PAMs based on an aryl glycine sulfonamide scaffold. Rodriguez AL, Zhou Y, Williams R, Weaver CD, Vinson PN, Dawson ES, Steckler T, Lavreysen H, Mackie C, Bartolomé JM, Macdonald GJ, Daniels JS, Niswender CM, Jones CK, Conn PJ, Lindsley CW, Stauffer SR (2012) Bioorg Med Chem Lett 22(24): 7388-92
    › Primary publication · 23142615 (PubMed) · PMC3539767 (PubMed Central)
  76. Unique signaling profiles of positive allosteric modulators of metabotropic glutamate receptor subtype 5 determine differences in in vivo activity. Rook JM, Noetzel MJ, Pouliot WA, Bridges TM, Vinson PN, Cho HP, Zhou Y, Gogliotti RD, Manka JT, Gregory KJ, Stauffer SR, Dudek FE, Xiang Z, Niswender CM, Daniels JS, Jones CK, Lindsley CW, Conn PJ (2013) Biol Psychiatry 73(6): 501-9
    › Primary publication · 23140665 (PubMed) · PMC3572342 (PubMed Central)
  77. Metabotropic glutamate receptors for new treatments in schizophrenia. Herman EJ, Bubser M, Conn PJ, Jones CK (2012) Handb Exp Pharmacol (213): 297-365
    › Primary publication · 23027420 (PubMed)
  78. Optimization of an ether series of mGlu5 positive allosteric modulators: molecular determinants of MPEP-site interaction crossover. Manka JT, Vinson PN, Gregory KJ, Zhou Y, Williams R, Gogi K, Days E, Jadhav S, Herman EJ, Lavreysen H, Mackie C, Bartolomé JM, Macdonald GJ, Steckler T, Daniels JS, Weaver CD, Niswender CM, Jones CK, Conn PJ, Lindsley CW, Stauffer SR (2012) Bioorg Med Chem Lett 22(20): 6481-5
    › Primary publication · 22981332 (PubMed) · PMC3755010 (PubMed Central)
  79. Discovery of N-(4-methoxy-7-methylbenzo[d]thiazol-2-yl)isonicatinamide, ML293, as a novel, selective and brain penetrant positive allosteric modulator of the muscarinic 4 (M4) receptor. Salovich JM, Vinson PN, Sheffler DJ, Lamsal A, Utley TJ, Blobaum AL, Bridges TM, Le U, Jones CK, Wood MR, Daniels JS, Conn PJ, Niswender CM, Lindsley CW, Hopkins CR (2012) Bioorg Med Chem Lett 22(15): 5084-8
    › Primary publication · 22738637 (PubMed) · PMC3401285 (PubMed Central)
  80. Novel allosteric agonists of M1 muscarinic acetylcholine receptors induce brain region-specific responses that correspond with behavioral effects in animal models. Digby GJ, Noetzel MJ, Bubser M, Utley TJ, Walker AG, Byun NE, Lebois EP, Xiang Z, Sheffler DJ, Cho HP, Davis AA, Nemirovsky NE, Mennenga SE, Camp BW, Bimonte-Nelson HA, Bode J, Italiano K, Morrison R, Daniels JS, Niswender CM, Olive MF, Lindsley CW, Jones CK, Conn PJ (2012) J Neurosci 32(25): 8532-44
    › Primary publication · 22723693 (PubMed) · PMC3398407 (PubMed Central)
  81. The role of aldehyde oxidase and xanthine oxidase in the biotransformation of a novel negative allosteric modulator of metabotropic glutamate receptor subtype 5. Morrison RD, Blobaum AL, Byers FW, Santomango TS, Bridges TM, Stec D, Brewer KA, Sanchez-Ponce R, Corlew MM, Rush R, Felts AS, Manka J, Bates BS, Venable DF, Rodriguez AL, Jones CK, Niswender CM, Conn PJ, Lindsley CW, Emmitte KA, Daniels JS (2012) Drug Metab Dispos 40(9): 1834-45
    › Primary publication · 22711749 (PubMed) · PMC3422546 (PubMed Central)
  82. The metabotropic glutamate receptor 8 agonist (S)-3,4-DCPG reverses motor deficits in prolonged but not acute models of Parkinson's disease. Johnson KA, Jones CK, Tantawy MN, Bubser M, Marvanova M, Ansari MS, Baldwin RM, Conn PJ, Niswender CM (2013) Neuropharmacology : 187-95
    › Primary publication · 22546615 (PubMed) · PMC3432150 (PubMed Central)
  83. The Discovery and Characterization of ML218: A Novel, Centrally Active T-Type Calcium Channel Inhibitor with Robust Effects in STN Neurons and in a Rodent Model of Parkinson's Disease. Xiang Z, Thompson AD, Brogan JT, Schulte ML, Melancon BJ, Mi D, Lewis LM, Zou B, Yang L, Morrison R, Santomango T, Byers F, Brewer K, Aldrich JS, Yu H, Dawson ES, Li M, McManus O, Jones CK, Daniels JS, Hopkins CR, Xie XS, Conn PJ, Weaver CD, Lindsley CW (2011) ACS Chem Neurosci 2(12): 730-742
    › Primary publication · 22368764 (PubMed) · PMC3285241 (PubMed Central)
  84. Discovery of 2-(2-benzoxazoyl amino)-4-aryl-5-cyanopyrimidine as negative allosteric modulators (NAMs) of metabotropic glutamate receptor 5 (mGlu₅): from an artificial neural network virtual screen to an in vivo tool compound. Mueller R, Dawson ES, Meiler J, Rodriguez AL, Chauder BA, Bates BS, Felts AS, Lamb JP, Menon UN, Jadhav SB, Kane AS, Jones CK, Gregory KJ, Niswender CM, Conn PJ, Olsen CM, Winder DG, Emmitte KA, Lindsley CW (2012) ChemMedChem 7(3): 406-14
    › Primary publication · 22267125 (PubMed) · PMC3517057 (PubMed Central)
  85. Muscarinic receptor pharmacology and circuitry for the modulation of cognition. Bubser M, Byun N, Wood MR, Jones CK (2012) Handb Exp Pharmacol (208): 121-66
    › Primary publication · 22222698 (PubMed)
  86. Development of a more highly selective M(1) antagonist from the continued optimization of the MLPCN Probe ML012. Melancon BJ, Lamers AP, Bridges TM, Sulikowski GA, Utley TJ, Sheffler DJ, Noetzel MJ, Morrison RD, Daniels JS, Niswender CM, Jones CK, Conn PJ, Lindsley CW, Wood MR (2012) Bioorg Med Chem Lett 22(2): 1044-8
    › Primary publication · 22197142 (PubMed) · PMC3434972 (PubMed Central)
  87. Roles of the M1 muscarinic acetylcholine receptor subtype in the regulation of basal ganglia function and implications for the treatment of Parkinson's disease. Xiang Z, Thompson AD, Jones CK, Lindsley CW, Conn PJ (2012) J Pharmacol Exp Ther 340(3): 595-603
    › Primary publication · 22135383 (PubMed) · PMC3286317 (PubMed Central)
  88. The metabotropic glutamate receptor 4-positive allosteric modulator VU0364770 produces efficacy alone and in combination with L-DOPA or an adenosine 2A antagonist in preclinical rodent models of Parkinson's disease. Jones CK, Bubser M, Thompson AD, Dickerson JW, Turle-Lorenzo N, Amalric M, Blobaum AL, Bridges TM, Morrison RD, Jadhav S, Engers DW, Italiano K, Bode J, Daniels JS, Lindsley CW, Hopkins CR, Conn PJ, Niswender CM (2012) J Pharmacol Exp Ther 340(2): 404-21
    › Primary publication · 22088953 (PubMed) · PMC3263969 (PubMed Central)
  89. Functional impact of allosteric agonist activity of selective positive allosteric modulators of metabotropic glutamate receptor subtype 5 in regulating central nervous system function. Noetzel MJ, Rook JM, Vinson PN, Cho HP, Days E, Zhou Y, Rodriguez AL, Lavreysen H, Stauffer SR, Niswender CM, Xiang Z, Daniels JS, Jones CK, Lindsley CW, Weaver CD, Conn PJ (2012) Mol Pharmacol 81(2): 120-33
    › Primary publication · 22021324 (PubMed) · PMC3263948 (PubMed Central)
  90. Discovery, synthesis, and structure-activity relationship development of a series of N-4-(2,5-dioxopyrrolidin-1-yl)phenylpicolinamides (VU0400195, ML182): characterization of a novel positive allosteric modulator of the metabotropic glutamate receptor 4 (mGlu(4)) with oral efficacy in an antiparkinsonian animal model. Jones CK, Engers DW, Thompson AD, Field JR, Blobaum AL, Lindsley SR, Zhou Y, Gogliotti RD, Jadhav S, Zamorano R, Bogenpohl J, Smith Y, Morrison R, Daniels JS, Weaver CD, Conn PJ, Lindsley CW, Niswender CM, Hopkins CR (2011) J Med Chem 54(21): 7639-47
    › Primary publication · 21966889 (PubMed) · PMC3226828 (PubMed Central)
  91. Discovery and characterization of novel subtype-selective allosteric agonists for the investigation of M(1) receptor function in the central nervous system. Lebois EP, Bridges TM, Lewis LM, Dawson ES, Kane AS, Xiang Z, Jadhav SB, Yin H, Kennedy JP, Meiler J, Niswender CM, Jones CK, Conn PJ, Weaver CD, Lindsley CW (2010) ACS Chem Neurosci 1(2): 104-121
    › Primary publication · 21961051 (PubMed) · PMC3180826 (PubMed Central)
  92. Muscarinic and nicotinic acetylcholine receptor agonists and allosteric modulators for the treatment of schizophrenia. Jones CK, Byun N, Bubser M (2012) Neuropsychopharmacology 37(1): 16-42
    › Primary publication · 21956443 (PubMed) · PMC3238081 (PubMed Central)
  93. (3-Cyano-5-fluorophenyl)biaryl negative allosteric modulators of mGlu(5): Discovery of a new tool compound with activity in the OSS mouse model of addiction. Lindsley CW, Bates BS, Menon UN, Jadhav SB, Kane AS, Jones CK, Rodriguez AL, Conn PJ, Olsen CM, Winder DG, Emmitte KA (2011) ACS Chem Neurosci 2(8): 471-482
    › Primary publication · 21927650 (PubMed) · PMC3172161 (PubMed Central)
  94. Impact of isoflurane anesthesia on D2 receptor occupancy by [18F]fallypride measured by microPET with a modified Logan plot. Tantawy MN, Peterson TE, Jones CK, Johnson K, Rook JM, Conn PJ, Baldwin RM, Ansari MS, Kessler RM (2011) Synapse 65(11): 1173-80
    › Primary publication · 21584868 (PubMed) · PMC4078917 (PubMed Central)
  95. The evolution of histamine H₃ antagonists/inverse agonists. Lebois EP, Jones CK, Lindsley CW (2011) Curr Top Med Chem 11(6): 648-60
    › Primary publication · 21261594 (PubMed)
  96. Discovery, synthesis, and structure-activity relationship development of a series of N-(4-acetamido)phenylpicolinamides as positive allosteric modulators of metabotropic glutamate receptor 4 (mGlu(4)) with CNS exposure in rats. Engers DW, Field JR, Le U, Zhou Y, Bolinger JD, Zamorano R, Blobaum AL, Jones CK, Jadhav S, Weaver CD, Conn PJ, Lindsley CW, Niswender CM, Hopkins CR (2011) J Med Chem 54(4): 1106-10
    › Primary publication · 21247167 (PubMed) · PMC3166797 (PubMed Central)
  97. Discovery of novel allosteric modulators of metabotropic glutamate receptor subtype 5 reveals chemical and functional diversity and in vivo activity in rat behavioral models of anxiolytic and antipsychotic activity. Rodriguez AL, Grier MD, Jones CK, Herman EJ, Kane AS, Smith RL, Williams R, Zhou Y, Marlo JE, Days EL, Blatt TN, Jadhav S, Menon UN, Vinson PN, Rook JM, Stauffer SR, Niswender CM, Lindsley CW, Weaver CD, Conn PJ (2010) Mol Pharmacol 78(6): 1105-23
    › Primary publication · 20923853 (PubMed) · PMC2993468 (PubMed Central)
  98. 3-Cyano-5-fluoro-N-arylbenzamides as negative allosteric modulators of mGlu(5): Identification of easily prepared tool compounds with CNS exposure in rats. Felts AS, Lindsley SR, Lamb JP, Rodriguez AL, Menon UN, Jadhav S, Jones CK, Conn PJ, Lindsley CW, Emmitte KA (2010) Bioorg Med Chem Lett 20(15): 4390-4
    › Primary publication · 20598884 (PubMed) · PMC2905502 (PubMed Central)
  99. The antipsychotic potential of muscarinic allosteric modulation. Bridges TM, LeBois EP, Hopkins CR, Wood MR, Jones CK, Conn PJ, Lindsley CW (2010) Drug News Perspect 23(4): 229-40
    › Primary publication · 20520852 (PubMed) · PMC4780339 (PubMed Central)
  100. Selective potentiation of the metabotropic glutamate receptor subtype 2 blocks phencyclidine-induced hyperlocomotion and brain activation. Hackler EA, Byun NE, Jones CK, Williams JM, Baheza R, Sengupta S, Grier MD, Avison M, Conn PJ, Gore JC (2010) Neuroscience 168(1): 209-18
    › Primary publication · 20350588 (PubMed) · PMC3598608 (PubMed Central)
  101. [(18)F]Fallypride dopamine D2 receptor studies using delayed microPET scans and a modified Logan plot. Tantawy MN, Jones CK, Baldwin RM, Ansari MS, Conn PJ, Kessler RM, Peterson TE (2009) Nucl Med Biol 36(8): 931-40
    › Primary publication · 19875049 (PubMed) · PMC2771119 (PubMed Central)
  102. Synthesis and structure-activity relationships of allosteric potentiators of the m(4) muscarinic acetylcholine receptor. Kennedy JP, Bridges TM, Gentry PR, Brogan JT, Kane AS, Jones CK, Brady AE, Shirey JK, Conn PJ, Lindsley CW (2009) ChemMedChem 4(10): 1600-7
    › Primary publication · 19705385 (PubMed) · PMC2887613 (PubMed Central)
  103. Discovery of molecular switches that modulate modes of metabotropic glutamate receptor subtype 5 (mGlu5) pharmacology in vitro and in vivo within a series of functionalized, regioisomeric 2- and 5-(phenylethynyl)pyrimidines. Sharma S, Kedrowski J, Rook JM, Smith RL, Jones CK, Rodriguez AL, Conn PJ, Lindsley CW (2009) J Med Chem 52(14): 4103-6
    › Primary publication · 19537763 (PubMed) · PMC3192011 (PubMed Central)
  104. Novel selective allosteric activator of the M1 muscarinic acetylcholine receptor regulates amyloid processing and produces antipsychotic-like activity in rats. Jones CK, Brady AE, Davis AA, Xiang Z, Bubser M, Tantawy MN, Kane AS, Bridges TM, Kennedy JP, Bradley SR, Peterson TE, Ansari MS, Baldwin RM, Kessler RM, Deutch AY, Lah JJ, Levey AI, Lindsley CW, Conn PJ (2008) J Neurosci 28(41): 10422-33
    › Primary publication · 18842902 (PubMed) · PMC2577155 (PubMed Central)
  105. Synthesis and SAR of analogues of the M1 allosteric agonist TBPB. Part I: Exploration of alternative benzyl and privileged structure moieties. Bridges TM, Brady AE, Kennedy JP, Daniels RN, Miller NR, Kim K, Breininger ML, Gentry PR, Brogan JT, Jones CK, Conn PJ, Lindsley CW (2008) Bioorg Med Chem Lett 18(20): 5439-42
    › Primary publication · 18805692 (PubMed) · PMC3177598 (PubMed Central)
  106. Centrally active allosteric potentiators of the M4 muscarinic acetylcholine receptor reverse amphetamine-induced hyperlocomotor activity in rats. Brady AE, Jones CK, Bridges TM, Kennedy JP, Thompson AD, Heiman JU, Breininger ML, Gentry PR, Yin H, Jadhav SB, Shirey JK, Conn PJ, Lindsley CW (2008) J Pharmacol Exp Ther 327(3): 941-53
    › Primary publication · 18772318 (PubMed) · PMC2745822 (PubMed Central)
  107. Discovery, characterization, and antiparkinsonian effect of novel positive allosteric modulators of metabotropic glutamate receptor 4. Niswender CM, Johnson KA, Weaver CD, Jones CK, Xiang Z, Luo Q, Rodriguez AL, Marlo JE, de Paulis T, Thompson AD, Days EL, Nalywajko T, Austin CA, Williams MB, Ayala JE, Williams R, Lindsley CW, Conn PJ (2008) Mol Pharmacol 74(5): 1345-58
    › Primary publication · 18664603 (PubMed) · PMC2574552 (PubMed Central)
  108. Biphenyl-indanone A, a positive allosteric modulator of the metabotropic glutamate receptor subtype 2, has antipsychotic- and anxiolytic-like effects in mice. Galici R, Jones CK, Hemstapat K, Nong Y, Echemendia NG, Williams LC, de Paulis T, Conn PJ (2006) J Pharmacol Exp Ther 318(1): 173-85
    › Primary publication · 16608916 (PubMed)
  109. New therapeutic frontiers for metabotropic glutamate receptors. Niswender CM, Jones CK, Conn PJ (2005) Curr Top Med Chem 5(9): 847-57
    › Primary publication · 16178730 (PubMed)